Conference reports

PROMISE results support WHO recommendations for pregnant and breastfeeding women: more needs to be done to improve ART acceptability and adherence

1 August 2016. Related: Conference reports, Pregnancy, Paediatric care, HIV prevention and transmission.

Sub-Saharan African countries moving quickly to recommend “Treat All”

1 August 2016. Related: Conference reports, Treatment access, Guidelines.

Efavirenz associated with suicide risk in analysis from START study

1 August 2016. Related: Conference reports, Side effects.

CD4:CD8 ratio is more sensitive marker of risk than CD4 counts in analysis from START study

1 August 2016. Related: Conference reports, Treatment strategies.

Treatment in primary HIV infection is significantly more likely to normalise CD4:CD8 ratio

1 August 2016. Related: Conference reports, Treatment strategies.

Publications launched at AIDS 2016

1 August 2016. Related: Conference reports, Other news.

8th International Workshop on HIV paediatrics, 15-16 July 2016, Durban, South Africa.

1 August 2016. Related: Conference reports.

No increased resistance with once daily dosing of abacavir and 3TC than twice daily dosing in the ARROW trial

1 August 2016. Related: Conference reports, Paediatric care, Drug resistance.

TB 2016, 16-17 July 2016, Durban, South Africa

1 August 2016. Related: Conference reports.

Universal treatment of multi-drug resistant TB is possible within current budgets with generic production

1 August 2016. Related: Conference reports, TB coinfection.

Shortened nine-month MDR-TB treatment works well in children and adolescents

1 August 2016. Related: Conference reports, Paediatric care, TB coinfection.

Levofloxacin: safety and tolerability in HIV positive and negative children treated for MDR-TB

1 August 2016. Related: Conference reports, Paediatric care, TB coinfection.

2016 Towards an HIV Cure Symposium, 16-17 July 2016, Durban, South Africa

1 August 2016. Related: Conference reports, Cure-related research.

17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, 8-10 June 2016, Washington DC, USA

1 August 2016. Related: Conference reports.

Modelling data might support use of low dose 400 mg efavirenz in pregnancy

1 August 2016. Related: Conference reports, Pregnancy.

Pharmacokinetics of antiretrovirals comparable to that in non-pregnant women from three weeks after delivery

1 August 2016. Related: Conference reports, Antiretrovirals, Pregnancy.

22nd Annual BHIVA Conference, 19-22 April 2016, Manchester

1 June 2016. Related: Conference reports.

New HBV drugs and non-viral liver disease in HIV positive people

1 June 2016. Related: Conference reports, Hepatitis coinfection, Basic science and immunology.

Non-AIDS mortality in England and Wales in HIV positive vs general population

1 June 2016. Related: Conference reports, Ageing and life expectancy, Research studies.

High prevalence of multiple high-risk HPV infections in young HIV positive gay men

1 June 2016. Related: Conference reports, Coinfections and complications, Vaccines and microbicides.

Anal cancer and HPV screening in HIV positive people

1 June 2016. Related: Conference reports, Cancer and HIV, Vaccines and microbicides.

Increasing demand for community treatment information services

1 June 2016. Related: Conference reports.

Non alcohol fatty acid liver disease: an emerging problem

1 June 2016. Related: Conference reports, Coinfections and complications.

HIV positive people on ART have impaired alveolar immunity

1 June 2016. Related: Conference reports, Antiretrovirals, Coinfections and complications.

International Liver Congress (EASL) 2016, 13-18 April 2016, Barcelona

1 June 2016. Related: Conference reports.

High cure rates using generic hepatitis C drugs bought online: EASL supports lower cost access for Western countries

1 June 2016. Related: Conference reports, Treatment access, Hepatitis coinfection, Other news.

Studies of new generic $300 HepC combination of ravidasvir and sofosbuvir for low-income countries

1 June 2016. Related: Conference reports, Antiretrovirals, Hepatitis coinfection.

23rd Conference on Retroviruses and Opportunistic Infections (CROI 2016), 22-25 February 2016, Boston

1 June 2016. Related: Conference reports.

No effect of tenofovir on infant bone mineral content in African study

1 June 2016. Related: Conference reports, Antiretrovirals, Pregnancy, Paediatric care.

Use of modelling to predicting paediatric dosing of long acting antiretrovirals

1 June 2016. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.

Nevirapine dosing for treatment of neonates

1 June 2016. Related: Conference reports, Paediatric care, PK and drug interactions.

START substudies: increased quality of life from earlier treatment but no impact on vascular function or cardiovascular markers

1 June 2016. Related: Conference reports, Antiretrovirals, Coinfections and complications.

Six-week ledipasvir/sofosbuvir in HIV positive patients with acute HCV

1 June 2016. Related: Conference reports, Hepatitis coinfection.

6th International Workshop on HIV & Women, 20-21 February 2016, Boston

1 June 2016. Related: Conference reports.

Doravirine can be co-administered with oral contraceptives

1 June 2016. Related: Conference reports, Women's health.

No increased risk of birth defects with darunavir: findings from the Antiretroviral Pregnancy Registry

1 June 2016. Related: Conference reports, Pregnancy.

23rd Conference on Retroviruses and Opportunistic Infections (CROI 2016), 22-25 February 2016, Boston

22 March 2016. Related: Conference reports.

Dual long-acting injections of cabotegravir plus rilpivirine: 32-week results from LATTE-2 study

22 March 2016. Related: Conference reports, Antiretrovirals.

New NRTI MK-8591 (EFdA): weekly oral dosing and once-yearly slow-release dosing has potential for HIV treatment and PrEP

22 March 2016. Related: Conference reports, Antiretrovirals.

Similar viral load reductions at week 4 when dolutegravir is used with 2- or 3-drug initial ART

22 March 2016. Related: Conference reports, Antiretrovirals.

48-week results for NNRTI doravirine compared to efavirenz

22 March 2016. Related: Conference reports, Antiretrovirals.

Dramatic increase in use of oral TDF/FTC for PrEP in the US – plus a few cautions

22 March 2016. Related: Conference reports, HIV prevention and transmission.

Future oral and long-acting formulations for PrEP: pills, films, gels, injections and depots

22 March 2016. Related: Conference reports, HIV prevention and transmission.

First data on TAF as PrEP to prevent HIV infection

22 March 2016. Related: Conference reports, HIV prevention and transmission.

Long-acting cabotegravir as PrEP protects macaques against IV exposure but will need two-monthly injections

22 March 2016. Related: Conference reports, HIV prevention and transmission.

Role for maraviroc as HIV PrEP likely to need dual combinations

22 March 2016. Related: Conference reports, HIV prevention and transmission.

Dapivirine PrEP vaginal ring shows only limited PrEP protection against HIV in African women

22 March 2016. Related: Conference reports, HIV prevention and transmission, Vaccines and microbicides.

Early data from dolutegravir use during pregnancy

22 March 2016. Related: Conference reports, Pregnancy.

Dolutegravir: 48 week results in children age 6 to 12 years old

22 March 2016. Related: Conference reports, Paediatric care.

New antiretrovirals could mean savings up to US $3 billion by 2025

22 March 2016. Related: Conference reports, Treatment access.

Countries with lower HIV prevalence have lower ART coverage

22 March 2016. Related: Conference reports, Antiretrovirals, Treatment access.

Nigerian herbal medicines widely used by HIV positive people can contain antiretrovirals

22 March 2016. Related: Conference reports, Antiretrovirals.

Cure research news from CROI 2016

22 March 2016. Related: Conference reports, Cure-related research.

46th World Conference on Lung Health of the International Union Against TB and Lung Disease

1 February 2016. Related: Conference reports.

Promising first results with a 9-month regimen for multidrug resistant tuberculosis in French-speaking African countries

1 February 2016. Related: Conference reports, TB coinfection.

Pharmacokinetics of old and new TB drugs for children

1 February 2016. Related: Conference reports, PK and drug interactions, TB coinfection.

The REALITY trial: cotrimoxazole/isoniazid/pyridoxine tablets are bioequivalent to individual products and are acceptable to participants

1 February 2016. Related: Conference reports, TB coinfection.

BHIVA Autumn Conference 2015, 12-13 November 2015, London

1 February 2016. Related: Conference reports.

Selected webcasts from BHIVA Autumn conference 2015

1 February 2016. Related: Conference reports, On the web.

15th European AIDS Conference (EACS), 21-24 October 2015, Barcelona

1 December 2015. Related: Conference reports.

Remarkable results with dolutegravir monotherapy

1 December 2015. Related: Conference reports, Antiretrovirals, Vaccines and microbicides.

First-line ART with dolutegravir plus 3TC: 24-week early results

1 December 2015. Related: Conference reports, Antiretrovirals, Treatment strategies.

New European HIV guidelines (October 2015): universal ART, first-line integrase and PrEP

1 December 2015. Related: Conference reports, Guidelines.

Impact of early ART on lung function: results on ART and COPD from START substudy

1 December 2015. Related: Conference reports, Coinfections and complications.

No difference in neuropsychological test results between early and delayed ART in START substudy

1 December 2015. Related: Conference reports, Side effects, Coinfections and complications.